Zina Sarif

Founder

Berlin, Germany9 yrs 11 mos experience

Most Likely To SwitchHighly Stable

Key Highlights

Founded Yendou to accelerate drug development.
Expert in oncology clinical research and project management.
Achieved significant quality improvements in clinical trials.

Stackforce AI infers this person is a Healthcare and Oncology Research Expert with strong project management skills.

Contact

Skills

Core Skills

Clinical OperationsProject ManagementClinical ResearchOncology ExpertiseQuality AssuranceRisk ManagementResearch

Other Skills

Clinical Operations InfrastructureSite ID to FPI timelinesOncologyResource Allocation ManagementQuality CheckOncology ResearchTherapeutic Strategies

About

Can we take a discovered molecule and turn it into an approved medicine fast (in 5–6 years), reliably (with technology that removes failure paths), and affordably (on a ~$300M budget maximum)? I founded Yendou to answer this question with a definitive “Hell Yes!” - Yendou's focus till Dec 2027: Shortening the Site ID to FPI timeline down to 6 months. If delays kill your trials, let’s talk. Zina, CEO & Founder, Yendou

Experience

Yendou

Founder & CEO

Jun 2022 – Present · 3 yrs 10 mos · On-site

Clinical Operations Infrastructure to accelerate Site ID to FPI timelines. Learn more at yendou.com

Clinical Operations InfrastructureSite ID to FPI timelinesClinical OperationsProject Management

Astrazeneca

2 roles

TROPION-Breast Portfolio Lead CRA

Jul 2021 – May 2022 · 10 mos

| Therapeutic Area: Oncology | Indication: Breast Cancer | IP: Dato-Dxt

OncologyClinical ResearchOncology Expertise

Clinical Research Associate - Oncology

Apr 2021 – May 2022 · 1 yr 1 mo

| Therapeutic Area: Oncology | Indication: Breast Cancer |
IPs: Camizestrant (oral SERD); ENHERTU (ADC: Trastuzumab-Deruxtecan);

OncologyClinical ResearchOncology Expertise

Parexel

Global Clinical Projects Lead Assistant | Oncology

Sep 2020 – Mar 2021 · 6 mos · Greater London, England, United Kingdom

| Therapeutic Area: Oncology | Indication: multiple myeloma | Client: johnson & johnson
Success Stories:
Resource Allocation management:
Analysis of Ressources of ongoing multinational PhIII Hematology Studies within the past 5 years; identified overbilling resource roles and functions, established a new resource forcast leading to a monthly resource reduction of 600 hrs per clinical study.
coordinated communication with COLs and FLs to adjust future resource allocations according to the established forcast.
Quality Check:
Identified high risk quality issues at site levels and coordinated communication with >50 CRAs leading to reduction of Quality issues from 45 to 3 within 14 days.
Risk Management plan:
reviewed study-specific risks and requested active mitigation actions from COLs and FLs, leading to clearing the status of all red flagged risks within the study.
Investigator payment cleanUp: cleared status of pending payments and invoices of >120 sites
Provided weekly reports on COVID-19 related risks for clinical trials to Global Project Leaders.

Resource Allocation ManagementQuality CheckRisk ManagementProject ManagementQuality Assurance

Charité - @skin cancer research centre

Research Scientist | Melanoma

May 2017 – Sep 2020 · 3 yrs 4 mos · Berlin Metropolitan Area

| Therapeutic Area: Oncology | Indication: melanoma
Developed novel therapeutic strategies to overcome melanoma resistance to MAPK inhibitors Dabrafenib and Trametinib, resulting in a poster presentation nomination at the German Cancer Conference 2020.
Discovered the role of pro-survival protein Mcl-1 in melanoma resistance to programmed cell death resulting in a keynote speaker nomination at the Dermato-oncology Conference 2020.
Authored 5 Abstracts, 3 Posters and 2 peer-reviewed articles, uncovering the relevance of Mcl-1 and ERK ½-Kinase inhibition in the future of targeted therapy for solid tumours

Oncology ResearchTherapeutic StrategiesResearchOncology Expertise